Skip to content
Trial Agents

Myriad RBM

Myriad RBM is recorded as a service provider in 59 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

59distinct trials
17recorded service labels
3trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 20 of 59 trials · Latest update first

CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis

Sponsor Scleroderma Research Foundation

Start (EU)
Latest update
Estimated end

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Sponsor Janssen Cilag International

Start (EU)
Latest update
Estimated end

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

Sponsor Bristol Myers Squibb International Corporation

Start (EU)
Latest update
Estimated end
Operational learnings available1 trial-level finding · Read insights
  • Enrollment to the nivolumab plus relatlimab 960 mg group was stopped on 19 July 2021 after two participants in that group died, to protect participant safety.

These findings describe the trial, not the service provider’s performance or responsibility.

A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end
Operational learnings available1 trial-level finding · Read insights
  • EEA countries enrolled 148 of 201 participants, with the largest country enrollment in Italy (59 participants), followed by France (27) and Spain (25).

These findings describe the trial, not the service provider’s performance or responsibility.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

Sponsor Bristol-Myers Squibb Services Unlimited Company

Start (EU)
Latest update
Estimated end

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Sponsor Bristol-Myers Squibb Services Unlimited Company

Start (EU)
Latest update
Estimated end

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or had Previously Received TNFα Inhibitor Treatment

Sponsor Bristol-Myers Squibb Services Unlimited Company

Start (EU)
Latest update
Estimated end

A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer

Sponsor Bristol Myers Squibb International Corporation

Start (EU)
Latest update
Estimated end
Operational learnings available1 trial-level finding · Read insights
  • Enrollment ranged from 1 participant in Austria to 97 in Spain; 337 of 769 participants were enrolled in EEA countries.

These findings describe the trial, not the service provider’s performance or responsibility.

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Sponsor Bristol-Myers Squibb Services Unlimited Company

Start (EU)
Latest update
Estimated end

PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)

Sponsor Sobi Inc.

Start (EU)
Latest update
Estimated end

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Sponsor Kartos Therapeutics Inc.

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for Myriad RBM?

The 2026-10-09 snapshot links Myriad RBM to 59 distinct CTIS trials. Recorded services include Laboratory services, Exploratory Serum Biomarkers analysis, Predose exploratory biomarkers, Analysis and reporting of SCD163 biomarker, among 17 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Myriad RBM?

The most frequently recorded therapeutic areas are Immunology, Rheumatology, Solid Tumor Oncology, Haematological Malignancies. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Myriad RBM conducted?

The linked trials record locations in 25 countries, including Spain, France, Italy, Poland, Germany. These are trial locations, not confirmed office locations or countries where Myriad RBM delivered services.

What can this page tell me about Myriad RBM's trial experience?

Browse 59 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Myriad RBM. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Myriad RBM Inc.

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.